

Ramucirumab RAISE


PRELIMINARY SCORE

CURATIVE



NON-CURATIVE

OS



ADJUSTMENTS

Quality of life



No QoL benefit

Serious and disabling adverse effects



Other adjustments



Ramucirumab RAISE

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

1



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: Treatment of patients with mCRC with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine

Experimental Arm: Ramucirumab + FOLFIRI (folinic acid, 5-fluorouracil, irinotecan)

Control Arm: FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) + placebo

